AAP
OVID icon

Arax Advisory Partners’s Ovid Therapeutics OVID Stock Holding History

Arax Advisory Partners’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$153 Hold
57
– – ﹤0.01% 5114
2026
Q1 		$127 Hold
57
– – ﹤0.01% 3593
2025
Q4 		$93 Sell
57
-83
-59% -$128 ﹤0.01% 3839
2025
Q3 		$182 Buy
+140
New +$121 ﹤0.01% 3456

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Arax Advisory Partners's OVID Position: Q2 2026 in Review

Arax Advisory Partners held its Ovid Therapeutics (OVID) position steady in Q2 2026 at 57 shares worth $153. The position accounts for ﹤0.01% of the portfolio, ranked #5114.

Arax Advisory Partners first reported a position in OVID in Q3 2025 and has held it in 4 quarters since. The position peaked at $182 in Q3 2025. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Arax Advisory Partners held 57 shares of Ovid Therapeutics worth $153 as of Q2 2026.
  • Arax Advisory Partners left its Ovid Therapeutics share count unchanged in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5114 holding.
  • Arax Advisory Partners first reported a position in Ovid Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Arax Advisory Partners's Ovid Therapeutics position peaked at $182 in Q3 2025.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.